Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving oxidoreductase
Reexamination Certificate
2007-01-30
2007-01-30
Gitomer, Ralph (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving oxidoreductase
C530S335000
Reexamination Certificate
active
11031292
ABSTRACT:
The present application relates to a sensitive and quantitative method using dansylated glutathione as a trapping agent for the detection of reactive metabolites in the field of drug discovery. The fluorescent tag attached to the dansylated glutathione does not impede the ability of glutathione to react with reactive metabolites.
REFERENCES:
patent: 6830897 (2004-12-01), Avery et al.
patent: 6995022 (2006-02-01), van Breemen et al.
patent: 2005/0287623 (2005-12-01), Yan et al.
Soglia et al. (Jul. 2, 2004) J Pharma Biomed Anal 36, 105-116.
Yan et al. (2004) Anal Chem 76, 6835-6847.
Chen, W.G. et al., “Reactive Metabolite Screen for Reducing Candidate Attrition in Drug Discovery”, Adv. Exp. Med. Biol., vol. 500, pp. 521-524 (2001).
Gardner, I. et al., “A Comparison of the Oxidation of Clozapine and Olanzapine to Reactive Metabolites and the Toxicity of these Metabolites to Human Leukocytes”, Molecular Pharmacology, vol. 53, pp. 991-998 (1998).
Graham, D.J. et al., “Troglitazone-Induced Liver Failure: A Case Study”, The American Journal of Medicine, vol. 114, pp. 299-306 (2003).
Hammermeister, D.E. et al., “Characterization of dansylated glutathione, glutathione disulfide, cysteine and cystine by narrow bore liquid chromatography/electrospray ionization mass spectrometry”, Rapid Communications in Mass Spectrometry, vol. 14, pp. 503-508 (2000).
Iverson, S. et al., “Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis”, Chemico-Biological Interactions, vol. 142, pp. 175-199 (2002).
Jones, D.P. et al., “Glutathione measurement in human plasma: Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC”, Clinica Chimica Acta, vol. 275, pp. 175-184 (1998).
Kassahun, K. et al., “Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission”, Chem. Res. Toxicol., vol. 14, No. 1, pp. 62-70 (2001).
Khojasteh-Bakht, S.C. et al., “Metabolism of (R)-(+)-pulegone and (R)-(+)-menthofuran by Human Liver Cytochrome P-450s: Evidence for Formation of a Furan Epoxide”, Drug Metabolism and Disposition, vol. 27, No. 5, pp. 574-580 (1999).
Li, A.P. et al., “A review of the common properties of drugs with idiosyncratic hepatotoxicity and the ‘multiple determinant hypothesis’ for the manifestation of idiosyncratic drug toxicity”, Chemico-Biological Interactions, vol. 142, pp. 7-23 (2002).
Maggs, J.L. et al., “The Metabolic Formation of Reactive Intermediates from Clozapine, a Drug Associated with Agranulocytosis in Man”, The Journal of Pharmacology and Experimental Therapeutics, vol. 275, No. 3, pp. 1463-1475 (1995).
Nelson, S.D., “Mechanisms of the Formation and Disposition of Reactive Metabolites That Can Cause Acute Liver Injury”, Drug Metabolism Reviews, vol. 27, Nos. 1 & 2, pp. 147-177 (1995).
Park, B.K. et al., “Advances in molecular toxicology—towards understanding idiosyncratic drug toxicity”, Toxicology, vol. 153, pp. 39-60 (2000).
Park, B.K. et al., “Metabolic activation in drug allergies”, Toxicology, vol. 158, pp. 11-23 (2001).
Smith, M.T., “Mechanisms of Troglitazone Hepatotoxicity”, Chemical Research in Toxicology, vol. 16, No. 6, pp. 679-687 (2003).
Tettey, J.N. et al., “Enzyme-Induction Dependent Bioactivation of Troglitazone and Troglitazone Quinone In Vivo”, Chem. Res. Toxicol., vol. 14, No. 8, pp. 965-974 (2001).
Uetrecht, J.P., “New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The ‘Danger Hypothesis’ and Innate Immune System”, Chemical Research in Toxicology, vol. 12, No. 5, pp. 387-395 (1999).
Gan Jinping
Harper Timothy W.
Humphreys William G.
Bristol--Myers Squibb Company
Duncan, Jr. Sammy G.
Gitomer Ralph
LandOfFree
Method for identifying drug metabolites with dansylated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying drug metabolites with dansylated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying drug metabolites with dansylated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735564